DAWN Q1 2023 Earnings — Day One Biopharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

DAWNDay One Biopharmaceuticals, Inc.

$2B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$89,000

Operating Income

-$46M

Net Income

-$42M

EPS (Diluted)

$-0.49

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$26M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$324M

Total Liabilities

$23M

Stockholders' Equity

$300M

Cash & Equivalents

$49M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$89,000	-$6,000	-1383.3%
Operating Income	-$46M	-$28M	-65.3%
Net Income	-$42M	-$28M	-52.8%